CIK 0000730272 · Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 042729386
- Phone
- 7814499560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,953,260
- in 5 filings, $6.0M under 10b5-1 plans
Net −$5,953,260. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-14 | BARTHELEMY NICOLAS Director | Grant or award · Stock Option (Right to Buy) | +2,239 | 2,239 | ||
| 2026-05-07 | MUIR GLENN P Director | Option exercise | +2,434 | $38.76 | $94K | 39,056 |
| 2026-05-07 | MUIR GLENN P Director | Option exercise · Stock Option (Right to Buy) | +2,434 | 2,434 | ||
| 2026-05-07 | Douglass Brian Robb CHIEF PRODUCT OFFICER | Shares withheld for taxes | −334 | $126.43 | $42K | 7,985 |
| 2026-04-21 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −3,832 | $140.00 | $536K | 54,246 |
| 2026-03-05 | Hughes Violetta CHIEF ACCOUNTING OFFICER | Grant or award | +2,466 | 6,608 | ||
| 2026-03-05 | KURIYEL RALF Senior VP, R&D | Grant or award | +5,284 | 20,062 | ||
| 2026-03-05 | KURIYEL RALF Senior VP, R&D | Grant or award · Stock Option (Right to Buy) | +5,669 | 5,669 | ||
| 2026-03-05 | Loeillot Olivier Chief Executive Officer | Grant or award | +24,134 | 58,078 | ||
| 2026-03-05 | Loeillot Olivier Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +25,890 | 25,890 | ||
| 2026-03-05 | Bylund James Chief Operating Officer | Grant or award | +7,751 | 25,423 | ||
| 2026-03-05 | Bylund James Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +8,315 | 8,315 | ||
| 2026-03-05 | Garland Jason K CFO | Grant or award | +7,751 | 20,092 | ||
| 2026-03-05 | Garland Jason K CFO | Grant or award · Stock Option (Right to Buy) | +8,315 | 8,315 | ||
| 2026-03-04 | Bylund James Chief Operating Officer | Grant or award | +125 | 17,734 | ||
| 2026-03-04 | Bylund James Chief Operating Officer | Shares withheld for taxes | −62 | $125.84 | $8K | 17,672 |
| 2026-03-04 | KURIYEL RALF Senior VP, R&D | Grant or award | +125 | 14,820 | ||
| 2026-03-04 | KURIYEL RALF Senior VP, R&D | Shares withheld for taxes | −42 | $125.84 | $5K | 14,778 |
| 2026-03-02 | Bylund James Chief Operating Officer | Shares withheld for taxes | −2,433 | $124.97 | $304K | 17,609 |
| 2026-03-02 | Loeillot Olivier Chief Executive Officer | Shares withheld for taxes | −1,610 | $124.97 | $201K | 33,944 |
Page 3 of 11 · 215 trades